Implandex La (Goserelin Acetate)

Goserelin acetate binds to pituitary GnRH receptors, initially causing a brief surge in luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). Continued exposure desensitizes the receptors, leading to a sustained fall in LH and FSH, which in turn markedly reduces testosterone and estrogen production.

The specific dose and administration schedule of Implandex La are determined by the prescribing physician based on the patient’s condition, disease stage and clinical response. Healthcare professionals follow approved labeling and individual patient needs when selecting the regimen.

The pregnancy and lactation categories for goserelin acetate are not established, and the drug is generally contraindicated during pregnancy and breastfeeding because it suppresses sex hormone production essential for fetal development and milk production. Use only if the potential benefit justifies the risk.

To request Implandex La, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Implandex La is comparable to other GnRH agonists such as leuprolide acetate. Both suppress gonadotropins and sex hormones, but formulation differences (e.g., depot duration) and dosing schedules may influence convenience and patient preference. Compared with surgical castration, goserelin offers a reversible, medical approach without permanent loss of gonadal function.

Implandex La must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and avoid exposing it to temperatures outside the recommended range to maintain potency.

Implandex La is administered by subcutaneous injection, typically in the abdomen or thigh. The injection is performed by a qualified healthcare professional using aseptic technique. The frequency (monthly, quarterly, or six‑monthly) depends on the prescribed regimen and the specific indication.

Serious risks include significant bone loss leading to osteoporosis or fractures, cardiovascular events such as hypertension or thromboembolism, severe allergic reactions (anaphylaxis), and rare pituitary apoplexy. Patients should be monitored regularly for these complications, and any concerning symptoms reported promptly.

Implandex La is contraindicated in individuals with known hypersensitivity to goserelin acetate or any formulation excipients, in pregnant or breastfeeding women unless the benefit outweighs the risk, and in patients with severe hepatic impairment where drug clearance may be compromised. Clinicians should assess each patient’s medical history before initiating therapy.